• Miscellaneous respiratory disorders

Xhance Generic Name & Formulations

General Description

Fluticasone propionate 93mcg/spray; aqueous nasal spray.

Pharmacological Class


How Supplied

Spray—16mL (120 sprays)


Generic Availability


Xhance Indications


Nasal polyps.

Xhance Dosage and Administration


≥18yrs: 1 spray in each nostril twice daily. Also, 2 sprays in each nostril twice daily may be effective in some patients. Max total daily doses: 2 sprays in each nostril twice daily (744mcg/day).


<18yrs: not established.

Xhance Contraindications

Not Applicable

Xhance Boxed Warnings

Not Applicable

Xhance Warnings/Precautions


Maintain regular regimen. Do not exceed recommended dose. Respiratory tract tuberculosis. Systemic infections. Ocular herpes simplex. Immunosuppression. If exposed to measles or chickenpox, consider anti-infective prophylactic therapy. If adrenal insufficiency exists following systemic corticosteroid therapy, replacement with topical corticosteroids may exacerbate symptoms of adrenal insufficiency (eg, lassitude, depression). Recent nasal ulceration, surgery, trauma; avoid until healing has occurred. Change in vision, history of increased intraocular pressure, glaucoma, and/or cataracts; monitor closely. Monitor for hypercorticism and HPA axis suppression (if occur discontinue gradually), and candida infection or other nasal mucosal changes. Discontinue if septal perforation occurs. Discontinue if hypersensitivity reactions occur. Prolonged immobilization, family history of osteoporosis, postmenopausal, tobacco use, advanced age, poor nutrition: monitor bone mineral density. Hepatic impairment: monitor. Pregnancy. Nursing mothers.

Xhance Pharmacokinetics


Human plasma protein bound at ~99%.


CYP3A4 pathway.


Fecal, renal (<5%). Half-life: ~7.8 hours.

Xhance Interactions


Concomitant strong CYP3A4 inhibitors (eg, ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, ketoconazole, telithromycin, conivaptan, lopinavir, voriconazole): not recommended. Additive effects with chronic use of drugs that can reduce bone mineral density (eg, anticonvulsants, oral corticosteroids): monitor.

Xhance Adverse Reactions

Adverse Reactions

Epistaxis, nasal septal ulceration/erythema, nasopharyngitis, nasal mucosal erythema/ulcerations, nasal congestion, acute sinusitis, headache, pharyngitis; impaired wound healing, reduced bone mineral density, HPA axis effects, reduced growth velocity in children.

Xhance Clinical Trials

See Literature

Xhance Note

Not Applicable

Xhance Patient Counseling

See Literature